Outpatient high-dose chemotherapy with autologous stem-cell rescue for hematologic and nonhematologic malignancies

Journal of Clinical Oncology

Volumn 15, Issue 1, 1997, Pages 11-17

  Meisenberg, B R ^a   Miller, W E ^a   McMillan, R ^a   Callaghan, M ^a   Sloan, C ^a   Brehm, T ^a   Kosty, M P ^a   Kroener, J ^a   Longmire, R ^a   Saven, A ^a   Piro, L D ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; MELPHALAN; MITOXANTRONE; THIOTEPA;

ADULT; AGED; ARTICLE; AUTOGRAFT; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HEMATOLOGIC DISEASE; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELOID LEUKEMIA; OUTPATIENT; OVARY CANCER; PRIORITY JOURNAL; SOLID TUMOR; STEM CELL TRANSPLANTATION;

EID: 0031022799     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.1.11     Document Type: Article

References (12)

1. Newcomer LN: Defining experimental therapy - Third-party payer's dilemma. N Engl J Med 323:1702-1704, 1990
2. Bennett CL, Armitage JL, Armitage GO, et al: Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: Results from the University of Nebraska 1987 through 1991. J Clin Oncol 13:969-973, 1995
3. Peters WP, Rogers MC: Variation in approval by insurance companies of coverage for autologous bone marrow transplantation for breast cancer. N Engl J Med 330:473-477, 1994
4. Peters WP, Ross M, Vredenburgh JJ, et al: The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer. Semin Oncol 21:25-31, 1994
5. Gilbert C, Meisenberg B, Vredenburgh J, et al: Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support. J Clin Oncol 12:1005-1011, 1994
6. Meisenberg B, Miller W, McMillan R: Lower dose cyclophosphamide (LDC) plus growth factor (GF) results in efficient and predictable mobilization (MZ) of peripheral blood progenitor cells (PBPC). Blood 86:988, 1995 (suppl 1, abstr)
7. Meisenberg B, McMillan R, Miller W: Sequential cycles of hish-dose chemotherapy (HDC) with autologous peripheral blood progenitor cells (PBPC). Proc Am Soc Clin Oncol 14:318, 1995 (abstr)
8. Antman K, Ayash L, Elias A, et al: A phase II study of high-dose cyclopriosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 10:102-110, 1992
9. Dunphy FR, Spitzer G, Buzdar AU, et al: Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double hish-dose chemotherapy intensification and bone marrow support. J Clin Oncol 8:1207-1216, 1990
10. Perry MC: The Chemotherapy Source Book. Baltimore, Williams & Wilkins, 1992, p 1133
11. Peters WP, Rosner G, Ross M, et al: Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 81:1709-1719, 1993
12. Dukelow K, Gilbert C, Kasprzak S, et al: Outpatient bone marrow transplantation: Two-year update. Proc Am Soc Clin Oncol 14:316, 1995 (abstr)